Role of Exenatide in NASH-a Pilot Study
NCT00650546 on ClinicalTrials.gov · last registry update 2017-04-11
A small phase 2/phase 3 — 8 participants, against a typical 60. The sponsor logged completion for August 2010. Primary outcome, as filed: Number of Patients With Improvement in Liver Histology After Treatment With Exenatide. exenatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Indiana University
- Sponsor type
- Other
- Enrollment
- 8
- Started
- 2006-08
- Primary completion
- 2010-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Patients With Improvement in Liver Histology After Treatment With Exenatide
Conditions studied
Nonalcoholic Fatty Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.